Hereditary ATTR amyloidosis
Alnylam and Invitae have partnered to offer genetic testing at no charge for adults 18 and over who may carry a gene mutation known to be associated with hereditary ATTR (hATTR) amyloidosis.
The Alnylam Act program was created to potentially enable diagnosis and to provide genetic counseling to help people make more informed decisions about their health.
Hypertrophic cardiomyopathy, dilated cardiomyopathy, long QT syndrome, Brugada syndrome, and other cardiomyopathies and arrhythmias.
The Detect Cardiomyopathy and Arrhythmia program offers sponsored, no-charge genetic testing and counseling for people suspected of having a familial cardiomyopathy or arrhythmia.
Cardiomyopathies and arrhythmias may have a genetic cause that affects prognosis and management. The Invitae Detect Cardiomyopathy and Arrhythmia program was created to reduce barriers to genetic testing and improve clinical outcomes.
The Invitae Detect Lysosomal Storage Diseases (LSDs) program provides sponsored, no-charge genetic testing and counseling for people suspected of having a lysosomal storage disease.
Invitae’s Detect LSDs program breaks down many barriers to genetic testing for LSDs. Through the program, individuals suspected of having a lysosomal disease have access to genetic testing and counseling to help bring them one step closer to a diagnosis and the appropriate clinical management.